J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment.
Heidi M. Crane,Stephanie A. Ruderman,Bridget M. Whitney,Robin M. Nance,Lydia N. Drumright,Allison R. Webel,Amanda L. Willig,Michael S. Saag,Katerina A. Christopoulos,Meredith Greene,Andrew W. Hahn,Joseph J. Eron,Sonia Napravnik,W. Christopher Mathews,Geetanjali Chander,Mary E. McCaul,Edward R. Cachay,Kenneth H. Mayer,Alan L. Landay,Steven N. Austad,Jimmy Ma,Stephen B. Kritchevsky,Chintan Pandya,Chad J. Achenbach,Francisco Cartujano-Barrera,Mari M. Kitahata,Joseph A C Delaney,Charles Kamen +27 more
TL;DR: In this article , the authors examined associations between frailty and drug, alcohol, and tobacco use among a large diverse cohort of people with HIV (PWH) in clinical care in the current era.
Journal ArticleDOI
1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial
Joseph J. Eron,Chloe Orkin,Douglas Cunningham,Federcio Pulido,Frank A. Post,Stéphane De Wit,Erkki Lathouwers,Veerle Hufkens,Romana Petrovic,Erika Van Landuyt +9 more
Journal ArticleDOI
Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study.
Sivaporn Gatechompol,Lu Zheng,Yajing Bao,Anchalee Avihingsanon,Stephen J. Kerr,Nagalingeswaran Kumarasamy,James Hakim,Frank Maldarelli,Robert J. Gorelick,Jorden L Welker,Jeffrey D. Lifson,Mina C. Hosseinipour,Joseph J. Eron,Kiat Ruxrungtham +13 more
TL;DR: In this article, the authors assessed the prevalence and factors associated with residual viremia in people with HIV (PWH), who were virally-suppressed on antiretroviral therapy (ART) in low and middle-income countries (LMIC).
Journal ArticleDOI
Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19.
Babafemi Taiwo,Kara W. Chew,Carlee Moser,David A. Wohl,Eric S. Daar,Jonathan Z. Li,Alexander L. Greninger,Christoph Bausch,Thomas C. Luke,Keila Hoover,Gene Neytman,Mark J. Giganti,Maxine Mei Zheng Olefsky,Arzhang Javan,Courtney V. Fletcher,Joseph J. Eron,Judith S. Currier,Michael Hughes,Davey M. Smith +18 more
TL;DR: SAB-185, a novel fully-human IgG polyclonal immunoglobulin product, underwent phase 2 evaluation for non-hospitalized adults with mild-moderate COVID-19 as discussed by the authors .